相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
Barbara Manzanares-Martin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
Haibo Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
Femke A. Ehlers et al.
CANCERS (2021)
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Cristina Capuano et al.
CANCERS (2021)
KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease
Joanna Debska-Zielkowska et al.
CELLS (2021)
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response
Dhon Romeo Makanga et al.
ONCOIMMUNOLOGY (2021)
Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+patients
Marjan Hematian Larki et al.
GENES AND IMMUNITY (2020)
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K. Erbe et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy
Hsu-Huan Chou et al.
BIOMEDICAL JOURNAL (2019)
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
Daniela Pende et al.
FRONTIERS IN IMMUNOLOGY (2019)
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
Martine Bagot et al.
LANCET ONCOLOGY (2019)
The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
Jessica C. Anania et al.
FRONTIERS IN IMMUNOLOGY (2019)
Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma
H. Haydaroglu et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
Christian Schmitt et al.
FRONTIERS IN IMMUNOLOGY (2017)
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/ HER2-Positive Breast Cancer Analysis of the NSABP B-31 Trial
Patrick G. Gavin et al.
JAMA ONCOLOGY (2017)
Cancer treatment and the KIR-HLA system: an overview
Patrizia Leone et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2017)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
Yayi He et al.
ONCOTARGET (2016)
KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
Cristina Morales-Estevez et al.
Frontiers in Immunology (2016)
Neuroblastoma patients with high-affinity FCGR2A,-3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
Nikolai Siebert et al.
OncoImmunology (2016)
NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+than Their iKIR Negative Counterparts
Gamze Isitman et al.
PLOS ONE (2016)
Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
E. Muraro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+breast cancer patients
Gianmaria Miolo et al.
BMC CANCER (2014)
KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
Grzegorz Terszowski et al.
JOURNAL OF IMMUNOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
Valli De Re et al.
PLOS ONE (2014)
Killer Cell Immunoglobulin-like Receptor Workshop: Insights into Evolution, Genetics, Function, and Translation
Karl-Johan Malmberg et al.
IMMUNITY (2011)
KIR/HLA combination associated with the risk of complications in celiac disease
Laura Caggiari et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2011)
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2
Simona Sivori et al.
BLOOD (2010)
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Alessandra Beano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Killer immunoglobulin-like receptors
L Moretta et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
N Tsavaris et al.
BRITISH JOURNAL OF CANCER (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
